Modeling of internal dose distributions during SR-89 treatment of a patient with bone metastases.
METHODS
A model of strontium biodistribution similar to the one created by the International Commission on Radiological Protection (ICRP) was applied for activity and absorbed dose calculations in a patient with bone metastases treated with Sr-89 strontium chloride. Metastases are represented just like all other organs and tissues collecting strontium. Data from the ICRP's standard Reference Man were used.


RESULTS
Results include calculated time-activity data for all model compartments and for relevant target organs. Absorbed doses per unit administered activity were calculated for blood (0.036 cGy/MBq), soft tissues (0.046 cGy/MBq), bone marrow (1.15 cGy/MBq), bone surface (1.45 cGy/MBq), upper large intestine (ULI) (0.13 cGy/MBq), lower large intestine (LLI) (0.38 cGy/MBq), bladder (0.12 cGy/MBq), and metastases (37.5 cGy/MBq).


CONCLUSIONS
Results of the absorbed dose calculations are comparable with results presented in references for specific clinical cases. Discrepancies in dose values may be effected by the size of metastases and the patient's condition.
Bialkowski
M M
MM
Radiation Oncology Center, Harper Hospital, Wayne State University, Detroit, MI 48201, USA.
Wierzbicki
J G
JG
Porter
A T
AT
D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000556:secondary; D006801:Humans; D011879:Radiotherapy Dosage; D013326:Strontium Radioisotopes / Q000627:therapeutic use*
D013326:Strontium Radioisotopes